Product Description
Bivalirudin is a direct thrombin inhibitor (DTI) frequently used for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention (PCI). Bivalirudin has a unique pharmacologic profile: unlike other marketed DTIs, it undergoes predominant non-organ elimination (proteolysis), and has the shortest half-life (approximately 25 min). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18449412/)
Mechanisms of Action: DT Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Canada | Chile | China | Colombia | Denmark | Dominican Republic | Egypt | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Lithuania | Netherlands | New Zealand | Peru | Philippines | Poland | Portugal | Romania | Russia | Slovenia | Spain | Sweden | Taiwan | Turkey | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Coronary Thrombosis | Thrombosis | Thrombocytopenia
Known Adverse Events: Injuries/wounds Unspecified
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|